Akari Therapeutics Surges on Promising KRAS Cancer Data and $5.5M Financing
Akari Therapeutics shares surged over 100% in premarket trading after its lead drug candidate AKTX-101 showed positive preclinical results in KRAS-mutated pancreatic cancer models and the company announced a $5.5 million private placement.
Markets
